secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001493152-25-021410
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate completes $6M debt financing, appoints Bryan Downey as CCO
--------------------------------------------------------------------

- Issued $6.57M unsecured promissory note at 9% interest, maturing 18 months, to Avondale Capital for $6M net proceeds.
- Bryan Downey appointed Chief Commercial Officer; granted 30,000 options at $3.80/share, vesting over 4 years.
- Cash runway extended into Q2 2026; proceeds for working capital and general corporate purposes.
- FDA accepted NDA for CTx-1301 (ADHD); PDUFA target action date May 31, 2026.
- Note includes monthly redemption up to $660k after PDUFA; company can defer up to 2 redemptions with 1% fee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315225021410/0001493152-25-021410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315225021410/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-021410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer